CN101677537A - 解联蛋白变体及其药学用途 - Google Patents
解联蛋白变体及其药学用途 Download PDFInfo
- Publication number
- CN101677537A CN101677537A CN200780051774A CN200780051774A CN101677537A CN 101677537 A CN101677537 A CN 101677537A CN 200780051774 A CN200780051774 A CN 200780051774A CN 200780051774 A CN200780051774 A CN 200780051774A CN 101677537 A CN101677537 A CN 101677537A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- amino acid
- viper
- albumen
- crotalin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (95)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87185406P | 2006-12-26 | 2006-12-26 | |
US60/871,854 | 2006-12-26 | ||
PCT/US2007/026125 WO2008088548A2 (en) | 2006-12-26 | 2007-12-21 | Disintegrin variants and pharmaceutical uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101677537A true CN101677537A (zh) | 2010-03-24 |
CN101677537B CN101677537B (zh) | 2016-08-17 |
Family
ID=39636522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200780051774.5A Expired - Fee Related CN101677537B (zh) | 2006-12-26 | 2007-12-21 | 解联蛋白变体及其药学用途 |
Country Status (16)
Country | Link |
---|---|
US (1) | US7943728B2 (zh) |
EP (2) | EP2124548B1 (zh) |
JP (3) | JP5908666B2 (zh) |
KR (1) | KR20090108049A (zh) |
CN (1) | CN101677537B (zh) |
AU (1) | AU2007343734B2 (zh) |
BR (1) | BRPI0720636A2 (zh) |
CA (1) | CA2672091A1 (zh) |
ES (1) | ES2389697T3 (zh) |
HK (1) | HK1136160A1 (zh) |
IL (1) | IL199564A (zh) |
MX (1) | MX2009007065A (zh) |
NZ (2) | NZ598176A (zh) |
RU (2) | RU2477727C2 (zh) |
TW (1) | TWI392738B (zh) |
WO (1) | WO2008088548A2 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106714818A (zh) * | 2014-08-22 | 2017-05-24 | 成功大学 | 去整合蛋白变异体及其医药用途 |
TWI698447B (zh) * | 2015-06-28 | 2020-07-11 | 新源生物科技股份有限公司 | 用於抑制血管新生之融合蛋白 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7943728B2 (en) * | 2006-12-26 | 2011-05-17 | National Cheng Kung University | Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases |
CN101481412B (zh) * | 2009-02-09 | 2011-08-10 | 吉林大学 | 一种具有抗肿瘤作用的多肽及其编码基因与应用 |
EP2456454A4 (en) * | 2009-07-20 | 2013-03-20 | Univ Nat Cheng Kung | FOR AV-3-INTEGRIN SELECTIVE POLYPEPTIDE AND PHARMACEUTICAL USES THEREOF ASSOCIATED WITH A HUMAN SERUM ALUMINUM (HSA) VARIATION |
US20120264212A1 (en) * | 2009-11-06 | 2012-10-18 | Virginia Tech Intellectual Properties, Inc. | Compounds and methods for inhibiting the metastasis of cancer cells |
CN102883738A (zh) * | 2009-12-23 | 2013-01-16 | 成功大学 | 治疗血管发生相关的眼部疾病的组合物和方法 |
ES2679400T3 (es) * | 2010-11-01 | 2018-08-27 | Industry-Academic Cooperation Foundation, Yonsei University | Composición para su uso para la disolución de trombos |
ES2687992T3 (es) | 2013-07-30 | 2018-10-30 | Industry-Academic Cooperation Foundation, Yonsei University | Proteína de fusión saxatilina-Fc y utilización de la misma |
KR101724129B1 (ko) * | 2014-03-28 | 2017-04-10 | 연세대학교 산학협력단 | Rgd 모티프를 포함하는 펩타이드 또는 단백질을 포함하는 신경염증 예방, 억제 또는 치료용 조성물 |
WO2016108669A1 (ko) * | 2014-12-31 | 2016-07-07 | 주식회사 휴온스 | Rgd 모티프 함유 펩티드 또는 이의 단편을 포함하는 화상 및 녹내장 치료, 피부 주름 개선 및 발모 촉진용 조성물 |
CN104774247B (zh) * | 2015-04-20 | 2018-06-05 | 中国药科大学 | 与整合素受体αvβ3相关的5肽 |
EP3510381A4 (en) | 2016-09-06 | 2020-07-29 | Debina Diagnostics, Inc. | NANODIAMANT PARTICLES AND RELATED DEVICES AND METHODS |
WO2018048477A1 (en) * | 2016-09-06 | 2018-03-15 | Debina Diagnostics, Inc. | Engineering and utility of fluorescent nanodiamond particles (ndp-f) for diagnostics and treatment of blood clots in human and veterinary medicine |
EP3665190B1 (en) * | 2017-08-09 | 2023-07-26 | National Taiwan University | Disintegrin variants and uses thereof |
AU2020296073A1 (en) * | 2019-06-18 | 2022-02-17 | Debina Diagnostics, Inc. | Compositions and articles comprising (nano)diamond particles |
BR102021016135A2 (pt) * | 2021-08-16 | 2023-02-23 | Novageia Biotecnologia Ltda | Antagonistas miméticos macrocíclicos com atividade biológica, seus usos e composições |
US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) * | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) * | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) * | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0206448B1 (en) * | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
US4791192A (en) * | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
EP0382451A3 (en) * | 1989-02-07 | 1991-05-29 | Merck & Co. Inc. | Viper venom polypeptides and variants |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
JPH05255395A (ja) * | 1990-10-26 | 1993-10-05 | Takeda Chem Ind Ltd | ポリペプチドおよびその製造法 |
US5380646A (en) * | 1992-10-19 | 1995-01-10 | Temple University Of The Commonwealth System Of Higher Education | Thrombus detection using radiolabelled disintegrins |
US6710030B1 (en) | 1993-10-22 | 2004-03-23 | University Of Southern California | Contortrostain (CN) and methods for its use in preventing metastasis and other conditions |
US5786324A (en) * | 1994-03-24 | 1998-07-28 | Regents Of The University Of Minnesota | Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use |
US5770565A (en) * | 1994-04-13 | 1998-06-23 | La Jolla Cancer Research Center | Peptides for reducing or inhibiting bone resorption |
AU781506B2 (en) * | 2000-02-03 | 2005-05-26 | Eisai R&D Management Co., Ltd. | Integrin expression inhibitors |
US6974884B2 (en) * | 2002-06-07 | 2005-12-13 | Wisconsin Alumni Research Foundation | Chemical synthesis of reagents for peptide coupling |
US7271245B2 (en) * | 2004-02-13 | 2007-09-18 | The Scripps Research Institute | Methods and compositions for inhibition of metastasis |
WO2007086879A2 (en) * | 2005-02-11 | 2007-08-02 | University Of Southern California | Method of expressing proteins with disulfide bridges |
US7943728B2 (en) * | 2006-12-26 | 2011-05-17 | National Cheng Kung University | Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases |
-
2007
- 2007-12-20 US US12/004,045 patent/US7943728B2/en not_active Expired - Fee Related
- 2007-12-21 EP EP07867921A patent/EP2124548B1/en not_active Not-in-force
- 2007-12-21 KR KR1020097015644A patent/KR20090108049A/ko not_active Application Discontinuation
- 2007-12-21 BR BRPI0720636-4A patent/BRPI0720636A2/pt not_active IP Right Cessation
- 2007-12-21 JP JP2009544049A patent/JP5908666B2/ja active Active
- 2007-12-21 NZ NZ598176A patent/NZ598176A/xx not_active IP Right Cessation
- 2007-12-21 EP EP20120171692 patent/EP2522676A3/en not_active Withdrawn
- 2007-12-21 MX MX2009007065A patent/MX2009007065A/es active IP Right Grant
- 2007-12-21 CA CA002672091A patent/CA2672091A1/en not_active Abandoned
- 2007-12-21 WO PCT/US2007/026125 patent/WO2008088548A2/en active Application Filing
- 2007-12-21 AU AU2007343734A patent/AU2007343734B2/en not_active Ceased
- 2007-12-21 ES ES07867921T patent/ES2389697T3/es active Active
- 2007-12-21 CN CN200780051774.5A patent/CN101677537B/zh not_active Expired - Fee Related
- 2007-12-21 NZ NZ577998A patent/NZ577998A/en not_active IP Right Cessation
- 2007-12-21 RU RU2009128647/10A patent/RU2477727C2/ru not_active IP Right Cessation
- 2007-12-25 TW TW096150026A patent/TWI392738B/zh active
-
2009
- 2009-06-25 IL IL199564A patent/IL199564A/en not_active IP Right Cessation
-
2010
- 2010-03-30 HK HK10103274.9A patent/HK1136160A1/xx not_active IP Right Cessation
-
2012
- 2012-11-16 RU RU2012148887/10A patent/RU2012148887A/ru not_active Application Discontinuation
-
2013
- 2013-02-20 JP JP2013031102A patent/JP2013151502A/ja active Pending
-
2015
- 2015-08-28 JP JP2015168912A patent/JP2016047818A/ja active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106714818A (zh) * | 2014-08-22 | 2017-05-24 | 成功大学 | 去整合蛋白变异体及其医药用途 |
TWI698447B (zh) * | 2015-06-28 | 2020-07-11 | 新源生物科技股份有限公司 | 用於抑制血管新生之融合蛋白 |
Also Published As
Publication number | Publication date |
---|---|
ES2389697T3 (es) | 2012-10-30 |
AU2007343734A2 (en) | 2009-09-03 |
JP2013151502A (ja) | 2013-08-08 |
EP2522676A2 (en) | 2012-11-14 |
US20080188413A1 (en) | 2008-08-07 |
AU2007343734B2 (en) | 2014-01-30 |
EP2124548A4 (en) | 2010-05-05 |
TWI392738B (zh) | 2013-04-11 |
EP2522676A3 (en) | 2013-02-27 |
WO2008088548A3 (en) | 2008-10-16 |
US7943728B2 (en) | 2011-05-17 |
JP2016047818A (ja) | 2016-04-07 |
CN101677537B (zh) | 2016-08-17 |
HK1136160A1 (en) | 2010-06-25 |
BRPI0720636A2 (pt) | 2014-01-07 |
TW200848070A (en) | 2008-12-16 |
MX2009007065A (es) | 2009-10-13 |
JP2010514444A (ja) | 2010-05-06 |
RU2009128647A (ru) | 2011-02-10 |
JP5908666B2 (ja) | 2016-04-26 |
IL199564A (en) | 2015-05-31 |
NZ598176A (en) | 2013-08-30 |
NZ577998A (en) | 2012-03-30 |
EP2124548B1 (en) | 2012-06-13 |
RU2012148887A (ru) | 2014-05-27 |
CA2672091A1 (en) | 2008-07-24 |
KR20090108049A (ko) | 2009-10-14 |
AU2007343734A1 (en) | 2008-07-24 |
WO2008088548A2 (en) | 2008-07-24 |
RU2477727C2 (ru) | 2013-03-20 |
EP2124548A2 (en) | 2009-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101677537B (zh) | 解联蛋白变体及其药学用途 | |
DE60036945T2 (de) | Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen | |
JP6420459B2 (ja) | 線維症抑制活性を有するペプチド及びこれを含む組成物 | |
ES2429034T3 (es) | Uso de antagonistas de ANGPTL3 para el tratamiento de enfermedades hepáticas | |
CN102470156A (zh) | 选择性作用于αvβ3整合素并缀合人血清白蛋白(HSA)变体的多肽及其药学用途 | |
CN107252486A (zh) | 激活素‑actrii的拮抗剂及在提高红细胞水平中的用途 | |
CN108129574A (zh) | 包括白细胞介素10和白细胞介素4的融合蛋白 | |
CN107969127A (zh) | Apoa-1融合多肽及相关组合物和方法 | |
US8183201B2 (en) | Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin | |
CN108367018A (zh) | 用于治疗淀粉样变性病的方法和组合物 | |
JP2016510596A (ja) | PTD−Smad7薬物療法 | |
US11560412B2 (en) | Compositions comprising GRIM-19 therapeutics and methods of use | |
JPH09502451A (ja) | 未結合mpl受容体を用いた血小板産生を刺激するための組成物および方法 | |
US8106002B2 (en) | Anti-cancer agent comprising protein C inhibitor | |
US20180028596A9 (en) | ANG-(1-7) Derivative Oligopeptides for the Treatment of Pain and Other Indications | |
CN111991408A (zh) | 槲皮素-3-o-刺槐糖苷作为钙离子通道的抑制剂的应用 | |
US20230212233A1 (en) | Novel mutant of recombinant ganoderma lucidum immunomodulatory protein and use thereof | |
TW202033562A (zh) | 一種雙功能血管生成抑制劑及其用途 | |
KR20130134628A (ko) | A형 인플루엔자 바이러스 감염 질환의 예방 및 치료용 조성물 | |
WO2002042448A1 (fr) | Nouveau polypeptide | |
CN107510844A (zh) | 含il-12和il-23抑制剂的制剂及其在促进骨形成中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: DCB USA LLC Effective date: 20140730 Owner name: NATIONAL CHENG KUNG UNIVERSITY Effective date: 20140730 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20140730 Address after: Taipei City, Taiwan, China Applicant after: National Taiwan University Address before: Taipei City, Taiwan, China Applicant before: National Taiwan University Applicant before: U.S. subsidiary of Biotechnology Development Center Effective date of registration: 20140730 Address after: Taipei City, Taiwan, China Applicant after: National Taiwan University Applicant after: National Cheng Kung University Address before: Taipei City, Taiwan, China Applicant before: National Taiwan University |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160817 Termination date: 20211221 |